One patient presented with thrombotic microangiopathy, and their other aPL either became negative after the use of plasmapheresis and rituximab or, in the case of lupus anticoagulant, could not be relied upon because of the use of heparin products. Here, FASLG is linked to Genetic thrombotic microangiopathy.